As per the report published by The Brainy Insights, the global bleeding disorders treatment market is expected to grow from USD 14.96 billion in 2022 to USD 30.80 billion by 2032, at a CAGR of 7.49% during the forecast period 2023-2032. The bleeding disorders treatment market is anticipated to grow at the fastest rate of 10.64% in Asia-Pacific. It is driven by an increase in the number of people with hemophilia. People are more likely to experience bleeding issues, and some medications or therapies can be used to manage these conditions. In addition, the rising cost of healthcare creates a significant opportunity for market growth.
The market is also driven by the development of novel therapies, such as gene therapy and non-factor replacement therapies, which are expected to offer more convenient and effective treatment options for patients. In addition, the increasing awareness about bleeding disorders and the availability of government support for research and development activities are expected to drive market growth.
The demand for bleeding disorders treatment is expected to grow due to the increasing prevalence of bleeding disorders such as hemophilia, von Willebrand disease, and others. Hemophilia is the most common bleeding disorder, affecting around 400,000 people worldwide. Additionally, the increasing incidence of injuries, surgeries, and accidents is also driving the demand for bleeding disorders treatment.
Leading companies in the industry include Alnylam Pharmaceuticals Inc., CSL Behring (CSL Limited), Johnson & Johnson, Octapharma AG, Sanofi S.A., Wellona Pharma, AbbVie Inc, Grifols S.A., Pfizer Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S among others, offer more significant opportunities and are continuously focused on new product developments and venture capital investments to obtain market share.
The global bleeding disorders treatment market has been segmented based on disease type, drug type, and region. The disease type segment is divided into hemophilia B, liver disease, hemophilia A, von willebrand disease, and others. The haemophilia A segment had the largest share of 24.06% and was valued at USD 3.59 billion in 2022 in the bleeding disorders treatment market. One of the three varieties of hemophilia having the uncommon and genetic blood illness is known as hemophilia A. It occurs when the blood doesn’t sufficiently clot. The drug type segment is divided into recombinant coagulation factor concentrates, antifibrinolytics, plasma-derived coagulation factor concentrates, fibrin sealants, desmopressin, and others. With a market value of USD 3.20 billion in 2022, the recombinant coagulation factor concentrates segment had the highest market share of 21.43%. Recombinant coagulation factors could be used as the primary treatment for those with hemophilia A/B or as a preventative measure.
The primary factors driving the expansion of the bleeding disorders treatment market are the rise in prevalence, technical advancements in managing bleeding disorders, and supportive governmental management initiatives. A surge in R&D studies, an increase in target patients, an increase in the diagnostic rate, and an increase in preventative therapy all contribute to the growth of the market for treating bleeding disorders. However, it is projected that factors including the high cost of treatment, a shortage of drugs, and serious adverse effects associated with plasma-derived products will restrain the market’s growth. On the other hand, the expanding bleeding disorders treatment market benefits from the improved knowledge of the disorder in developing countries.
